{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:34:17Z","timestamp":1775590457269,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.brachy.2019.01.006","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T21:44:54Z","timestamp":1550612694000},"page":"299-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial"],"prefix":"10.1016","volume":"18","author":[{"given":"Steven","family":"Tissaverasinghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanita","family":"Crook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Bachand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deidre","family":"Batchelar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Hilts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Bainbridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Farnquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2019.01.006_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2019.01.006_bib2","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/American college of radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.juro.2010.09.099","article-title":"Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy","volume":"185","author":"Stone","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2019.01.006_bib4","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5489\/cuaj.12121","article-title":"The best method for dose escalation: prostate brachytherapy","volume":"6","author":"Morton","year":"2012","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.brachy.2019.01.006_bib6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.urology.2008.07.064","article-title":"Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer","volume":"73","author":"Morris","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2019.01.006_bib7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.juro.2017.07.089","article-title":"Long-term prostate specific antigen stability and predictive factors of failure after permanent seed prostate brachytherapy","volume":"199","author":"Tetreault-Laflamme","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2019.01.006_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2017.02.015","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer: review of the current status","volume":"29","author":"Tselis","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.brachy.2019.01.006_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ijrobp.2014.11.018","article-title":"Brachytherapy improves biochemical failure\u2013free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis","volume":"91","author":"Smith","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.2018.36.6_suppl.47","article-title":"Ten year treatment outcomes of radical prostatectomy vs external beam radiation therapy vs. brachytherapy for 1,503 patients with intermediate risk prostate cancer","volume":"36","author":"Goy","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib11","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ijrobp.2010.04.038","article-title":"10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients","volume":"80","author":"Crook","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2019.01.006_bib12","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.juro.2008.03.133","article-title":"12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer","volume":"179","author":"Potters","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2019.01.006_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0360-3016(02)02733-5","article-title":"Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer","volume":"53","author":"Martinez","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2019.01.006_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ijrobp.2011.05.001","article-title":"High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable\/intermediate-risk prostate cancer: preliminary toxicity data","volume":"83","author":"Ghilezan","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clon.2004.12.005","article-title":"The emerging role of high-dose-rate brachytherapy for prostate cancer","volume":"17","author":"Morton","year":"2005","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.brachy.2019.01.006_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.brachy.2016.11.002","article-title":"High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer","volume":"16","author":"Patel","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2019.01.006_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ijrobp.2015.10.011","article-title":"Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer","volume":"94","author":"Jawad","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.brachy.2014.05.006","article-title":"Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion","volume":"13","author":"Crook","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2019.01.006_bib21","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.brachy.2017.02.003","article-title":"Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: initial findings of a randomized clinical trial","volume":"16","author":"Major","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2019.01.006_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging \u2013 reporting and data system: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2019.01.006_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/(SICI)1096-9098(199709)66:1<65::AID-JSO13>3.0.CO;2-N","article-title":"Interstitial implantation techniques in prostate cancer","volume":"66","author":"Sylvester","year":"1997","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/srao.2002.28667","article-title":"Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes","volume":"12","author":"Blasko","year":"2002","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.brachy.2012.03.007","article-title":"Ultrasound-CT fusion compared with MR-CT fusion for postimplant dosimetry in permanent prostate brachytherapy","volume":"12","author":"Bowes","year":"2013","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2019.01.006_bib26","first-page":"e1243","article-title":"Unexpected seed migration in prostate brachytherapy implants coincident with change in seed stranding product","volume":"9","author":"Rose","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.brachy.2019.01.006_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.prnil.2017.09.003","article-title":"Late seed migration after prostate brachytherapy with Iod-125 permanent implants","volume":"6","author":"Maletzki","year":"2018","journal-title":"Prostate Int"},{"key":"10.1016\/j.brachy.2019.01.006_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1748-717X-6-130","article-title":"Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds","volume":"6","author":"Sugawara","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5114\/jcb.2014.42026","article-title":"High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective","volume":"6","author":"Yoshioka","year":"2014","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2019.01.006_bib30","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1259\/bjr\/15403217","article-title":"High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer","volume":"85","author":"Challapalli","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1016\/j.brachy.2019.01.006_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.semradonc.2008.04.007","article-title":"Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer","volume":"18","author":"Ritter","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib32","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.ijrobp.2011.05.034","article-title":"Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor","volume":"81","author":"Otsuka","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00261-016-0871-z","article-title":"Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review","volume":"42","author":"Hassanzadeh","year":"2017","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.brachy.2019.01.006_bib34","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1464-410X.2010.10039.x","article-title":"Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy","volume":"108","author":"Mouraviev","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2019.01.006_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijrobp.2007.03.065","article-title":"Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence","volume":"69","author":"Pucar","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.brachy.2013.08.006","article-title":"Whole prostate D90 and V100: a dose\u2013response analysis of 2000 consecutive 125I monotherapy patients","volume":"13","author":"Morris","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2019.01.006_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2009.04.049","article-title":"Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: a prospective comparative toxicity analysis","volume":"77","author":"Gaudet","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib38","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.brachy.2016.09.004","article-title":"Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: results of a prospective study","volume":"15","author":"Vigneault","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2019.01.006_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.radonc.2016.02.004","article-title":"Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial","volume":"119","author":"Gomez-Iturriaga","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2019.01.006_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.brachy.2013.10.011","article-title":"Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study","volume":"13","author":"Mason","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2019.01.006_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.brachy.2008.07.002","article-title":"Inter-institutional variation of implant activity for permanent prostate brachytherapy","volume":"7","author":"Aronowitz","year":"2008","journal-title":"Brachytherapy"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472118307049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472118307049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:14:49Z","timestamp":1761531289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472118307049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1538472118307049"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2019.01.006","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2019.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}